CA
NZ
UK
AU
IND
US
• Initial equity award to Dr. Kreher valued at approximately $450,000, with annual grants of about $300,000.
• The presentation is available on the company’s investor relations platform.
• Provectus Biopharmaceuticals (OTC: PVCT) approved the conversion of $542,500 in accrued director fees into Series D-1 Preferred Stock.
• Stoke Therapeutics (NASDAQ: STOK) has fully enrolled participants in its Phase 3 EMPEROR study for zorevunersen, a potential Dravet syndrome therapy.
• Tenax Therapeutics and Orion Corporation finalized a supply agreement for levosimendan, with provisions for renewals.
• The board appoints Han Eui Seok as Chair of the Compensation Committee, effective June 30, 2026.
• Jupiter Neurosciences, Inc. Has announced the appointment of Dr. Tomas J. Philipson to its Board of Directors, effective June 26, 2026.
• On June 24 2026 KORU Medical and Command Medical Products executed Amendment No. 1 to their 2024 manufacturing agreement.
• Joseph Manhede appointed as Principal Accounting Officer.
• Nuvectis Pharma (NASDAQ: NVCT) priced 5,000,000 shares at $20.00 per share in a firm commitment offering.
Please wait processing your request...